{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:59:04Z","timestamp":1781801944852,"version":"3.54.5"},"reference-count":39,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CHAN23Y5"],"award-info":[{"award-number":["CHAN23Y5"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KOHLER23H0"],"award-info":[{"award-number":["KOHLER23H0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MAHER24B0"],"award-info":[{"award-number":["MAHER24B0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PHILLI12A0"],"award-info":[{"award-number":["PHILLI12A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF)-related diabetes (CFRD) affects nearly half of adults with CF, but screening rates with the recommended oral glucose tolerance test (OGTT) are low. We evaluated the utility of a nonfasting, 50-g, 1-h oral glucose challenge test (GCT) as first-line screening for CFRD and pre-CFRD. The objectives were to define a cutoff that provides high sensitivity and reasonable specificity, and to determine how GCT compares with other opportunistic tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Participants with CF \u226510 years old, without known diabetes, had baseline random plasma and capillary glucose (RPG and RCG), then underwent an in-clinic GCT for collection of 1-h plasma glucose (GCTpl). This was followed by hemoglobin A1C (HbA1c) and OGTT on a separate day. Receiver operating characteristic (ROC) curves were generated for identifying CFRD and pre-CFRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 185 participants, 94 had normal glucose tolerance, 81 had pre-CFRD, and 10 had CFRD. For detecting pre-CFRD or CFRD, GCTpl had an area under the ROC curve (ROC-AUC) of 0.73 (95% CI 0.65\u20130.80), higher than ROC-AUCs for RPG of 0.56 (0.48\u20130.65, P = 0.003), RCG of 0.55 (0.46 = 0.63, P = 0.002), and HbA1c of 0.62 (0.53\u20130.67, P = 0.02). The ROC-AUC for detecting CFRD was 0.75 (0.64\u20130.86) for GCTpl, 0.64 (0.42\u20130.87) for RPG, and 0.56 (0.39\u20130.73) for HbA1c. A GCTpl of 147 mg\/dL provides 90% sensitivity and 58% specificity for detecting CFRD and could reduce the OGTTs needed by 56%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>GCT offers a practical, in-clinic method for CFRD screening. This spares low-risk individuals from OGTT, while maintaining high sensitivity for CFRD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2806","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:26:17Z","timestamp":1774891577000},"page":"882-888","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Screening for Diabetes and Prediabetes in Cystic Fibrosis Using a Nonfasting 50-Gram 1-Hour Oral Glucose Challenge Test"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7430-7915","authenticated-orcid":false,"given":"Monique D.","family":"Maher","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 1 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Vigers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 1 , Aurora, CO"},{"name":"Biostatistics and Informatics, Colorado School of Public Health 2 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-4012","authenticated-orcid":false,"given":"Celia","family":"Kohler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 1 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene A.","family":"Stecenko","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Asthma, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta 3 , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-5147","authenticated-orcid":false,"given":"Antoinette","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota 4 , Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7672","authenticated-orcid":false,"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 1 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-8046","authenticated-orcid":false,"given":"Lawrence S.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Joseph Maxwell Cleland Atlanta VA Medical Center 5 , Decatur, GA"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Emory University School of Medicine 6 , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026061812461262300_B1","unstructured":"Cystic Fibrosis Foundation\n          . Cystic Fibrosis Foundation Patient Registry - 2023 annual data report.Bethesda, MD, Cystic Fibrosis Foundation, 2024"},{"key":"2026061812461262300_B2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026061812461262300_B3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ppul.1142","article-title":"Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis","volume":"32","author":"Koch","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"2026061812461262300_B4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpeds.2007.09.025","article-title":"Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis","volume":"152","author":"Bismuth","year":"2008","journal-title":"J Pediatr"},{"key":"2026061812461262300_B5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"2026061812461262300_B6","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in cystic fibrosis-related diabetes epidemiology between 2003 and 2018 from the U.S. Cystic Fibrosis Foundation Patient Registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/diab.43.8.1020","article-title":"Insulin sensitivity in cystic fibrosis","volume":"43","author":"Moran","year":"1994","journal-title":"Diabetes"},{"key":"2026061812461262300_B9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026061812461262300_B10","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2337\/dc23-0380","article-title":"Cystic Fibrosis-Related Diabetes Workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes","volume":"46","author":"Putman","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B11","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"key":"2026061812461262300_B12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"key":"2026061812461262300_B13","first-page":"860","article-title":"Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy","volume":"90","author":"Rolon","year":"2001","journal-title":"Acta Paediatr"},{"key":"2026061812461262300_B14","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Associationnd a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061812461262300_B16","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(24)00146-2","article-title":"WS07.01. Personalized CFRD prediction model can reduce OGTT frequency in low-risk individuals without delaying CFRD diagnosis","volume":"23","author":"Wu","year":"2024","journal-title":"J Cystic Fibros"},{"key":"2026061812461262300_B17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41436-020-01073-x","article-title":"Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth","volume":"23","author":"Lin","year":"2021","journal-title":"Genet Med"},{"key":"2026061812461262300_B18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026061812461262300_B19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155\u2009mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2026061812461262300_B21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2013.06.001","article-title":"Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test","volume":"13","author":"Schmid","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2026061812461262300_B22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026061812461262300_B23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2026061812461262300_B24","unstructured":"Team RC\n          . R: a language and environment for statistical computing. Accessed 25 June 2025. Available from https:\/\/www.R-project.org\/"},{"key":"2026061812461262300_B25","doi-asserted-by":"crossref","first-page":"1183288","DOI":"10.3389\/fendo.2023.1183288","article-title":"A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers","volume":"14","author":"Hicks","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061812461262300_B26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2020.01.003","article-title":"Abnormal glucose tolerance and the 50-gram glucose challenge test in cystic fibrosis","volume":"19","author":"Sheikh","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026061812461262300_B27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"JAMA"},{"key":"2026061812461262300_B28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ppul.23237","article-title":"Elevation of one hour plasma glucose during oral glucose tolerance testing","volume":"50","author":"Sheikh","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"2026061812461262300_B29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.311.7006.655","article-title":"Glucose tolerance in patients with cystic fibrosis: five year prospective study","volume":"311","author":"Lanng","year":"1995","journal-title":"BMJ"},{"key":"2026061812461262300_B30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/dme.14181","article-title":"Impact of mismatches in HbA1c vs glucose values on the diagnostic classification of diabetes and prediabetes","volume":"37","author":"Gonzalez","year":"2020","journal-title":"Diabet Med"},{"key":"2026061812461262300_B31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis\u2013related diabetes: a first Canadian clinical practice guideline","volume":"49","author":"Coriati","year":"2024","journal-title":"Can J Diabetes"},{"key":"2026061812461262300_B32","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic fibrosis\u2012related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","volume":"45","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"key":"2026061812461262300_B33","doi-asserted-by":"crossref","first-page":"101455","DOI":"10.1016\/j.diabet.2023.101455","article-title":"A glycosylated hemoglobin A1c above 6% (42 mmol\/mol) is associated with a high risk of developing cystic fibrosis-related diabetes and a lower probability of weight gain in both adults and children with cystic fibrosis","volume":"49","author":"Potter","year":"2023","journal-title":"Diabetes Metab"},{"key":"2026061812461262300_B34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2026061812461262300_B35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"key":"2026061812461262300_B36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc14-1140","article-title":"Type 1 diabetes through the life span: a position statement of the American Diabetes Association","volume":"37","author":"Chiang","year":"2014","journal-title":"Diabetes Care"},{"key":"2026061812461262300_B37","doi-asserted-by":"crossref","first-page":"e067946","DOI":"10.1136\/bmj-2021-067946","article-title":"Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis","volume":"377","author":"Ye","year":"2022","journal-title":"BMJ"},{"key":"2026061812461262300_B38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061812461262300_B39","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/5\/882\/860645\/dc252806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/5\/882\/860645\/dc252806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:46:22Z","timestamp":1781801182000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/5\/882\/164647\/Screening-for-Diabetes-and-Prediabetes-in-Cystic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2806","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}